Deutivacaftor
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2024
- First approval year
- 2024
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Deutivacaftor
- Molecular weight
- 401.55
- Structure (SMILES)
These details could not be displayed.
- deutivacaftor component of alyftrek
- Deutivacaftor component of alyftrek
- 3 quinolinecarboxamide n 2 1 1 dimethylethyl 4 1 1 di methyl d3 ethyl 2 2 2 d3 5 hydroxyphenyl 1 4 dihydro 4 oxo
- 3-QUINOLINECARBOXAMIDE, N-(2-(1,1-DIMETHYLETHYL)-4-(1,1-DI(METHYL-D3)ETHYL- 2,2,2-D3)-5-HYDROXYPHENYL)-1,4-DIHYDRO-4-OXO-
- ctp 656
- Ctp-656
- CTP-656
- d9 ivacaftor
- D9-ivacaftor
- deuterated ivacaftor
- Deuterated ivacaftor
- deutivacaftor
- Deutivacaftor
- deutivacaftor [INN]
- DEUTIVACAFTOR [USAN]
- Deutivacaftor [WHO-DD]
- deutivacaftor inn
- deutivacaftor usan
- deutivacaftor who dd
- ivacaftor d9
- Ivacaftor d9
- vx 561
- Vx-561
- VX-561
- CAS registry numbers
- 1413431-07-8
- ChEMBL ID
- CHEMBL4297603
- InChIKey
- PURKAOJPTOLRMP-ASMGOKTBSA-N
- PubChem compound IDs
- 71470491
- RxNorm IDs (RxCUI)
- 2701430
- FDA ingredient codes (UNII)
- SHA6U5FJZL
- Applicant
- VERTEX PHARMS INC
- Approval date
- 20 Dec 2024
- Application number
- NDA218730
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- deutivacaftor
- Type
- Synthetic organic
- Drug name stem
- -caftor; deu-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Mechanism
- Cystic fibrosis transmembrane conductance regulator activator
- Action type
- ACTIVATOR
- Target
- Cystic fibrosis transmembrane conductance regulator
- Protein identifier
- P13569
- Action
- Potentiation
- Action type
- POTENTIATION
- Target
- CFTR
- Gene symbol
- CFTR
- Protein identifier
- P13569
- Median affinity
- 6.59
- Affinity units
- pEC50
Open Targets mechanisms
- Mechanism
- Cystic fibrosis transmembrane conductance regulator activator
- Action type
- ACTIVATOR
- Target
- Cystic fibrosis transmembrane conductance regulator
Investigated indications
- Condition
- Cystic Fibrosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0009061
- Subject identifier
- D003550
- Condition identifier
- MONDO_0009061
- Condition identifier
- MONDO_0009061
- Highest recorded phase
- 4
- Event
- anaemia
- Reports
- 3
- Reporting signal score
- 121.903
- Event
- arthralgia
- Reports
- 34
- Reporting signal score
- 92.1204
- Event
- asthenia
- Reports
- 30
- Reporting signal score
- 94.9865
- Event
- chest discomfort
- Reports
- 213
- Reporting signal score
- 140.753
- Event
- cough
- Reports
- 307
- Reporting signal score
- 93.5883
- Event
- cystic fibrosis
- Reports
- 293
- Reporting signal score
- 1,198.45
- Event
- cystic fibrosis lung
- Reports
- 22
- Reporting signal score
- 102.279
- Event
- cystic fibrosis respiratory infection suppression
- Reports
- 149
- Reporting signal score
- 777.268
- Event
- distal intestinal obstruction syndrome
- Reports
- 35
- Reporting signal score
- 143.455
- Event
- fall
- Reports
- 25
- Reporting signal score
- 98.9497
- Event
- forced expiratory volume decreased
- Reports
- 111
- Reporting signal score
- 336.487
- Event
- haemoptysis
- Reports
- 166
- Reporting signal score
- 243.158
- Event
- hospitalisation
- Reports
- 797
- Reporting signal score
- 1,226.93
- Event
- hypotension
- Reports
- 5
- Reporting signal score
- 114.04
- Event
- infection
- Reports
- 388
- Reporting signal score
- 353.645
- Event
- infective pulmonary exacerbation of cystic fibrosis
- Reports
- 1,801
- Reporting signal score
- 9,298.19
- Event
- influenza
- Reports
- 175
- Reporting signal score
- 107.378
- Event
- liver function test increased
- Reports
- 120
- Reporting signal score
- 146.861
- Event
- lung infection
- Reports
- 108
- Reporting signal score
- 157.256
- Event
- lung transplant
- Reports
- 57
- Reporting signal score
- 124.254
- Event
- neutropenia
- Reports
- 4
- Reporting signal score
- 85.1164
- Event
- pain
- Reports
- 33
- Reporting signal score
- 132.748
- Event
- pain in extremity
- Reports
- 13
- Reporting signal score
- 88.6917
- Event
- pruritus
- Reports
- 18
- Reporting signal score
- 85.981
- Event
- pseudomonas infection
- Reports
- 76
- Reporting signal score
- 149.189
And 5 more, listed on the interactive page.
- NCT02971839
- NCT03224351
- NCT03227471
- NCT03911713
- NCT03912233
- NCT05033080
- NCT05076149
- NCT05422222
- NCT05437120
- NCT05444257
- NCT05535959
- Dose
- 2 tablets of vanzacaftor 10 mg/tezacaftor 50 mg/deutivacaftor 125 mg
- Route
- Oral
- How often
- Once daily
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 3
- Polar surface area
- 82.19
- Calculated partition coefficient (ALogP)
- 5.08
- Calculated partition coefficient (XLogP)
- 5.6
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 2
- Heavy atoms
- 29
- Molecular formula
- C24H28N2O3
- Monoisotopic mass
- 401.26648347
- Natural product
- No
- 51167-121
- 51167-135
Related records
Trials (8)
- A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
- A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
- A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
- A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
- Food Effect Study of CTP-656 in Healthy Male Volunteers
- Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656
- Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
In development for (1)
- Cystic fibrosis Phase 3
Targets (1)
- CFTR Cystic fibrosis transmembrane conductance regulator activator